Eric Blasius Risser - Mar 4, 2024 Form 4 Insider Report for MACROGENICS INC (MGNX)

Role
Chief Operating Officer
Signature
/s/ Lynn M. Cilinski, Attorney-in-fact
Stock symbol
MGNX
Transactions as of
Mar 4, 2024
Transactions value $
-$661,251
Form type
4
Date filed
3/6/2024, 04:20 PM
Previous filing
Feb 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGNX Common Stock Options Exercise $152K +15K +23.06% $10.15 80.1K Mar 4, 2024 Direct
transaction MGNX Common Stock Sale -$300K -15K -18.74% $20.00 65.1K Mar 4, 2024 Direct F1
transaction MGNX Common Stock Sale -$514K -26.2K -40.21% $19.63 38.9K Mar 4, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Employee stock option (right to buy) Options Exercise $0 -15K -8.82% $0.00 155K Mar 4, 2024 Common Stock 15K $10.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/21/2022.
F2 This transaction was executed in multiple trades at prices ranging from $19.50 to $19.78. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.